SE9600820D0 - Antibodies and their use - Google Patents

Antibodies and their use

Info

Publication number
SE9600820D0
SE9600820D0 SE9600820A SE9600820A SE9600820D0 SE 9600820 D0 SE9600820 D0 SE 9600820D0 SE 9600820 A SE9600820 A SE 9600820A SE 9600820 A SE9600820 A SE 9600820A SE 9600820 D0 SE9600820 D0 SE 9600820D0
Authority
SE
Sweden
Prior art keywords
mcp
antibody
screening
relates
antibodies
Prior art date
Application number
SE9600820A
Other languages
English (en)
Inventor
Jose Mario Mellado Garcia
Jose Miguel Rodriguez Frade
Carlos Martinez Alonso
Peter Lind
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9600820A priority Critical patent/SE9600820D0/sv
Publication of SE9600820D0 publication Critical patent/SE9600820D0/sv
Priority to JP09530879A priority patent/JP2000510685A/ja
Priority to ES97906403T priority patent/ES2210496T3/es
Priority to DK97906403T priority patent/DK0914345T3/da
Priority to AU21104/97A priority patent/AU724037B2/en
Priority to DE69727382T priority patent/DE69727382T2/de
Priority to PT97906403T priority patent/PT914345E/pt
Priority to PCT/SE1997/000342 priority patent/WO1997031949A1/en
Priority to EP97906403A priority patent/EP0914345B1/en
Priority to AT97906403T priority patent/ATE258560T1/de
Priority to US08/734,171 priority patent/US6084075A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
SE9600820A 1996-03-01 1996-03-01 Antibodies and their use SE9600820D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9600820A SE9600820D0 (sv) 1996-03-01 1996-03-01 Antibodies and their use
AT97906403T ATE258560T1 (de) 1996-03-01 1997-02-27 Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden
AU21104/97A AU724037B2 (en) 1996-03-01 1997-02-27 Antibodies binding to monocyte chemoattractant protein 1 (MCP-1) receptor (CCR2)
ES97906403T ES2210496T3 (es) 1996-03-01 1997-02-27 Anticuerpos que se unen al receptor (ccr2) de la proteina quimiotactica de monocitos 1 (mcp-1).
DK97906403T DK0914345T3 (da) 1996-03-01 1997-02-27 Antistoffer, som binder til monocyt-kemoattraktant-protein-1-receptor (MCP-1-receptor) (CCR2)
JP09530879A JP2000510685A (ja) 1996-03-01 1997-02-27 単球化学誘引タンパク質１（ｍｃｐ―１）レセプター（ｃｃｒ２）に結合する抗体
DE69727382T DE69727382T2 (de) 1996-03-01 1997-02-27 Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden
PT97906403T PT914345E (pt) 1996-03-01 1997-02-27 Ligacao de anticorpos a receptores (ccr2) de proteina 1 de quimio-atraccao de monocitos (pqm-1)
PCT/SE1997/000342 WO1997031949A1 (en) 1996-03-01 1997-02-27 Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2)
EP97906403A EP0914345B1 (en) 1996-03-01 1997-02-27 Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2)
US08/734,171 US6084075A (en) 1996-03-01 1997-02-28 Agonist and antagonist antibodies to the chemokine receptor-2 (CCR2)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600820A SE9600820D0 (sv) 1996-03-01 1996-03-01 Antibodies and their use

Publications (1)

Publication Number Publication Date
SE9600820D0 true SE9600820D0 (sv) 1996-03-01

Family

ID=20401642

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600820A SE9600820D0 (sv) 1996-03-01 1996-03-01 Antibodies and their use

Country Status (11)

Country Link
US (1) US6084075A (sv)
EP (1) EP0914345B1 (sv)
JP (1) JP2000510685A (sv)
AT (1) ATE258560T1 (sv)
AU (1) AU724037B2 (sv)
DE (1) DE69727382T2 (sv)
DK (1) DK0914345T3 (sv)
ES (1) ES2210496T3 (sv)
PT (1) PT914345E (sv)
SE (1) SE9600820D0 (sv)
WO (1) WO1997031949A1 (sv)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0740701B1 (en) 1994-01-13 2006-12-06 The Regents of the University of California Mammalian monocyte chemoattractant protein receptors
US20020019026A1 (en) * 1995-06-05 2002-02-14 Daniel R. Soppet Human g-protein receptor hgber32
GB9705521D0 (en) * 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
EP1002081B1 (en) 1997-08-14 2006-06-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Delayed progression to aids by a missense allele of the ccr2 gene
DK1053256T3 (da) * 1998-01-26 2011-10-03 Genentech Inc Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
CA2399080C (en) * 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
AU2004208716B2 (en) * 2000-02-03 2007-01-04 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
EP1783227A1 (en) * 2000-02-03 2007-05-09 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
AU4574501A (en) 2000-03-17 2001-10-03 Millennium Pharm Inc Method of inhibiting stenosis and restenosis
EP1455820A2 (en) * 2001-03-09 2004-09-15 William Herman Targeted ligands
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
KR100598309B1 (ko) * 2001-06-07 2006-07-10 케모센트릭스, 인크. 세포 이동성 검사
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AU2002357770B2 (en) 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20050142539A1 (en) * 2002-01-14 2005-06-30 William Herman Targeted ligands
WO2003077834A2 (en) * 2002-03-15 2003-09-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
CA2507080C (en) 2002-11-27 2015-01-06 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactic proteins
AU2003300293B8 (en) * 2002-12-20 2010-01-14 Chemocentryx, Inc. Inhibitors of the binding of chemokines I-TAC or SDF-1 to the CCXCKR2 receptor
US20050148507A1 (en) * 2003-05-02 2005-07-07 Boehringer Ingelheim International Gmbh Method for the production of an N-terminally modified chemotactic factor
US20100247540A1 (en) * 2003-10-30 2010-09-30 Chemocentryx, Inc. Methods and Compositions For Modulating Angiogenesis
US20080299130A1 (en) * 2004-05-04 2008-12-04 University Of Kentucky Research Foundation Methods And Compositions For The Treatment Of Ocular Neovascularization
AU2006233927A1 (en) 2005-04-15 2006-10-19 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
PT1871804E (pt) * 2005-04-21 2013-10-31 Chemocentryx Inc Anticorpos que ligam ccx-ckr2
DE102006015341A1 (de) * 2006-04-03 2007-10-04 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
CN101616689A (zh) * 2006-10-05 2009-12-30 森托科尔奥索生物科技公司 用于治疗纤维化的ccr2拮抗剂
RU2547595C2 (ru) 2008-08-18 2015-04-10 Пфайзер Инк Антитела против ccr2
WO2014064192A1 (en) 2012-10-26 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction
WO2016081801A1 (en) * 2014-11-21 2016-05-26 Millennium Pharmaceuticals, Inc. Use of an anti-ccr2 antagonist in the treatment of an infectious disease
US11846629B2 (en) 2016-09-20 2023-12-19 Tulane University MonoMac-1 cells expressing CD16 and CD163
JP6824689B2 (ja) * 2016-10-27 2021-02-03 株式会社ナリス化粧品 真皮シミ予防・改善剤及び／又はマクロファージ誘引剤のスクリーニング方法
CN110087530A (zh) 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
AU2018256406A1 (en) 2017-04-19 2019-10-17 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES
CN113164777A (zh) 2018-09-27 2021-07-23 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
TW202233251A (zh) 2020-11-09 2022-09-01 日商武田藥品工業股份有限公司 抗體藥物綴合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3664176B2 (ja) * 1992-11-10 2005-06-22 ジェネンテック・インコーポレーテッド Ｃ−ｃ ｃｋｒ−１，ｃ−ｃケモカインレセプター
US5652133A (en) * 1993-01-28 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor
EP0740701B1 (en) * 1994-01-13 2006-12-06 The Regents of the University of California Mammalian monocyte chemoattractant protein receptors
DE19503303A1 (de) * 1995-02-02 1996-08-08 Teves Gmbh Alfred Filtersystem mit selbsttätigem Filterwechsel für Kraftfahrzeuge

Also Published As

Publication number Publication date
AU724037B2 (en) 2000-09-07
JP2000510685A (ja) 2000-08-22
US6084075A (en) 2000-07-04
DE69727382D1 (de) 2004-03-04
DE69727382T2 (de) 2004-11-04
WO1997031949A1 (en) 1997-09-04
ATE258560T1 (de) 2004-02-15
DK0914345T3 (da) 2004-05-10
EP0914345A1 (en) 1999-05-12
ES2210496T3 (es) 2004-07-01
EP0914345B1 (en) 2004-01-28
AU2110497A (en) 1997-09-16
PT914345E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
SE9600820D0 (sv) Antibodies and their use
AU1679395A (en) Mammalian monocyte chemoattractant protein receptors
ATE150977T1 (de) Markiertes monocyte-chemoattractant- proteinmaterial und medizinische anwendung
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
ATE142506T1 (de) Verabreichung von antisensen oligonukleotiden und peptiden als arzeneimittel an geweben in vivo und an zellen durch verwendung von avidin-biotin- technologie
DE69926630D1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
WO2000078813A3 (en) Huntington disease cellular model: stably transfected pc12 cells expressing mutant huntingtin
PL336635A1 (en) Proteins of human tool-like receptor and their associated reagents and methods
ATE391778T1 (de) Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen
ATE110172T1 (de) Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
DE69736976D1 (de) Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
DE3750342T2 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
EP1908837A3 (en) Human receptor proteins, related reagents and methods
WO1995019435A3 (en) T cell antigen receptor v region proteins and methods of preparation thereof
CA2207505A1 (en) Neurological drug screens
ATE265533T1 (de) Saeugetierchemokine
CA2242750A1 (en) Antibodies with reduced net positive charge
DE19525784A1 (de) Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
DE3582191D1 (de) Verwendung eines spezifischen karzinomassoziierenden antigens (hapten), fucosylsialosylgangliotetrose (fuc-gm1) in diagnostischen und therapeutischen verfahren betreffend den menschlichen lungenkrebs (carcinomas von kleinen zellen).
ES2151665T3 (es) Procedimiento y equipo para predecir la respuesta terapeutica de un farmaco contra un tumor maligno.
ATE184286T1 (de) Hgpiib-fragmente und ihre verwendung in in-vitro- verfahren zur bestimmung von in vivo stattfindenden thrombotischen ereignissen
WO1998041538A3 (en) Novel human cytokine/steroid receptor protein
DE29508576U1 (de) Antikörper gegen das 42kDa-Protein aus Säugerzellen und Testsysteme zur Tumordiagnostik